AIDS, HIV
Conditions
Brief summary
Human Immunodeficiency Virus (HIV) infected patients who meet the entry criteria for the maraviroc pivotal trials (Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients, MOTIVATE) will be identified from the EuroSIDA HIV cohort. The rates of specific clinical adverse events in this identified patient population will be compared with the rates of these events in the participants of the MOTIVATE trials.
Detailed description
All patients in EuroSIDA cohort that meet the entry criteria of MOTIVATE trials are included without any sampling.
Interventions
OTHERmaraviroc
No intervention is distributed during this trial.
Sponsors
Copenhagen HIV Programme
Pfizer
ViiV Healthcare
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged over 16 at baseline. * Viral Load (VL) \> 5000 copies/ml at baseline (and measured in 6 months prior to baseline). * No changes in antiretroviral (ARV) regimens in the month period prior to baseline, or on no ARVs in the month prior to baseline. * \> 3 months exposure (sequential or cumulative) to at least 3 of the following; * Any nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) * Non-nucleoside reverse transcriptase inhibitor (NNNRTI) * Protease Inhibitor (PI ) * Enfuvirtide
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Malignancy | Median follow up of 3 years |
| Opportunistic infection | Median follow up of 3 years |
| Myocardial infarction | Median follow up of 3 years |
| All cause death | Median follow up of 3 years |
| Liver related death | Median follow up of 3 years |
Outcome results
None listed